Received Jul 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (NOVAVAX)) | NOVAVAX | UNK | — | OT |
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
I've noticed a mucosal response having had every combo; Nose tingles during any exposure; My nose tingles during any exposure; This non serious initial spontaneous report was reported by a Consumer via social media monitoring and concerns an individual of unspecified age and sex who experienced I'VE NOTICED A MUCOSAL RESPONSE HAVING HAD EVERY COMBO on an unknown day after receiving Novavax COVID-19 Vaccine, Adjuvanted (2024 - 2025 Formula) on an unknown date. At the time of the report, the outcome of the Mucosal disorder was Unknown. PFIZER BIONTECH COVID-19 VACCINE was also considered suspect. On 08-May-2025, significant information was received from the consumer via Resolver compliance (Resolver number 00345634). On an unspecified date after vaccination, the consumer experienced "nose tingles during any exposure" (PT: Intranasal paraesthesia). The reporter further informed that it started after the second Novavax shot; a second therapy dose was captured with unknown dates. At the time of the report, on 08-May-2025, the outcome of Intranasal paraesthesia was unknown.; Sender's Comments: This individual of an unspecified age and sex experienced Mucosal disorder and Intranasal paraesthesia after vaccination with Novavax COVID-19 Vaccine, Adjuvanted (2024 - 2025 Formula). The event Mucosal disorder and Intranasal paraesthesia were reported as non-serious. Based on the spontaneous nature of the report, the causal relationship between Novavax COVID-19 Vaccine, Adjuvanted (2024 - 2025 Formula) and Mucosal disorder and Intranasal paraesthesia is considered Possible.